Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY(TM) Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health

Stock Information for Dare Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dare Bioscience Inc.

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.